Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Casaluce

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Reviews on Recent Clinical Trials|March 31, 2016
Overcoming Resistance to EGFR Inhibitors in NSCLCPaolo Maione, Paola C Sacco, Francesca Casaluce, et al.
Current Medicinal Chemistry|November 19, 2016
The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung CancerPaolo Maione, Assunta Sgambato, Francesca Casaluce, et al.
Current Pharmaceutical Design|July 30, 2015
New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung CancerPaola Claudia Sacco, Paolo Maione, Antonio Rossi, et al.
Expert Review of Respiratory Medicine|March 24, 2015
Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancerPaola Claudia Sacco, Paolo Maione, Antonio Rossi, et al.
Expert Opinion on Pharmacotherapy|February 16, 2016
Optimal drugs for second-line treatment of patients with small-cell lung cancerAntonio Rossi, Paola Claudia Sacco, Assunta Sgambato, et al.
Expert Opinion on Emerging Drugs|September 26, 2014
Emerging drugs targeting PD-1 and PD-L1: reality or hope?Francesca Casaluce, Assunta Sgambato, Paola Claudia Sacco, et al.
Expert Review of Anticancer Therapy|October 21, 2015
Agents in the preclinical development stage for non-small cell lung cancerPaola Claudia Sacco, Assunta Sgambato, Francesca Casaluce, et al.
Expert Opinion on Pharmacotherapy|August 2, 2013
Medical treatment of small cell lung cancer: state of the art and new developmentAssunta Sgambato, Francesca Casaluce, Paolo Maione, et al.
Current Drug Safety|September 29, 2015
Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its ManagementAssunta Sgambato, Francesca Casaluce, Paola C Sacco, et al.
Translational Lung Cancer Research|July 18, 2017
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Andrea Ardizzoni, Massimo Barberis, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Reviews on Recent Clinical Trials|March 31, 2016
Overcoming Resistance to EGFR Inhibitors in NSCLCPaolo Maione, Paola C Sacco, Francesca Casaluce, et al.
Current Medicinal Chemistry|November 19, 2016
The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung CancerPaolo Maione, Assunta Sgambato, Francesca Casaluce, et al.
Current Pharmaceutical Design|July 30, 2015
New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung CancerPaola Claudia Sacco, Paolo Maione, Antonio Rossi, et al.
Expert Review of Respiratory Medicine|March 24, 2015
Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancerPaola Claudia Sacco, Paolo Maione, Antonio Rossi, et al.
Expert Opinion on Pharmacotherapy|February 16, 2016
Optimal drugs for second-line treatment of patients with small-cell lung cancerAntonio Rossi, Paola Claudia Sacco, Assunta Sgambato, et al.
Expert Opinion on Emerging Drugs|September 26, 2014
Emerging drugs targeting PD-1 and PD-L1: reality or hope?Francesca Casaluce, Assunta Sgambato, Paola Claudia Sacco, et al.
Expert Review of Anticancer Therapy|October 21, 2015
Agents in the preclinical development stage for non-small cell lung cancerPaola Claudia Sacco, Assunta Sgambato, Francesca Casaluce, et al.
Expert Opinion on Pharmacotherapy|August 2, 2013
Medical treatment of small cell lung cancer: state of the art and new developmentAssunta Sgambato, Francesca Casaluce, Paolo Maione, et al.
Current Drug Safety|September 29, 2015
Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its ManagementAssunta Sgambato, Francesca Casaluce, Paola C Sacco, et al.
Translational Lung Cancer Research|July 18, 2017
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Andrea Ardizzoni, Massimo Barberis, et al.
Pageof 4